IGF-1 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
==== MeSH D12.125.481 – glycine ==== MeSH D12.125.481.100 – allylglycine MeSH D12.125.481.700 – n-substituted glycines MeSH D12.125.481.700.249 – glycocholic acid MeSH D12.125.481.700.249.420 – glycodeoxycholic acid MeSH D12.125.481.700.249.420.400 – glycochenodeoxycholic acid MeSH D12.125.481.700.374 – sarcosine MeSH D12.125.481.700.500 – thiopronine MeSH D12.125.481.700.750 – thiorphan
Up to the 20th century, alcoholic spirits were assessed in the UK by mixing with gunpowder and testing the mixture to see whether it would still burn; spirit that just passed the test was said to be at 100° proof. The UK now uses percentage alcohol by volume (ABV) at 20 °C (68.0 °F), where spirit at 100° proof is approximately 57.15% ABV. In the US, "proof number" is defined as twice the ABV at 60 °F (15.6 °C).
Dynamic allele-specific hybridization (DASH) genotyping takes advantage of the differences in the melting temperature in DNA that results from the instability of mismatched base pairs. The process can be vastly automated and encompasses a few simple principles. In the first step, a genomic segment is amplified and attached to a bead through a PCR reaction with a biotinylated primer. In the second step, the amplified product is attached to a streptavidin column and washed with NaOH to remove the unbiotinylated strand. An allele-specific oligonucleotide is then added in the presence of a molecule that fluoresces when bound to double-stranded DNA. The intensity is then measured as temperature is increased until the melting temperature (Tm) can be determined. A SNP will result in a lower than expected Tm. Because DASH genotyping is measuring a quantifiable change in Tm, it is capable of measuring all types of mutations, not just SNPs. Other benefits of DASH include its ability to work with label free probes and its simple design and performance conditions.
=== Higher education === During his 2022 gubernatorial campaign, Moore called a plan to cancel up to $20,000 in federal student loan debt a "good first step" and said he would push the Biden administration to forgive more federal student debt if elected governor. In June 2023, Moore opposed the U.S. Supreme Court's ruling in Students for Fair Admissions v. Harvard, which held that race-based affirmative action in college admissions violated the Equal Protection Clause, calling it a "misguided ruling". In April 2024, Moore signed into law a bill banning legacy admissions at Maryland colleges and universities.
Sources: en.wikipedia.org
== Veterinary use == In the 17th century Robert Boyle investigated opium as a poison by giving opium to a dog. This experiment is the earliest documented use of an opioid in a domestic animal. In 1659, Christopher Wren and Boyle induced stupor in a dog via intravenous administration. Friedrich Wilhelm Adam Sertürner after isolating morphine from opium administered an aqueous alcoholic solution of morphine to four dogs and a mouse — one dog died and the others experienced sedation, convulsion, and emesis. Frederick Hobday was the first to report the varied effects of morphine in different species: in 1908 Hobday reported that morphine causes delirium in cats and horses but for dogs it induced anaesthesia. Hobday proposed that dogs be given 1/16th of a grain per pound to induce analgesia and anaesthesia in dogs. Despite the understanding of morphine's use in dogs it was not considered useful for other animals and in 1917, Howard Jay Milks wrote that morphine did not induce analgesia in animals other than dogs. Milks did report that 2 to 5 grains of morphine induced sedation in horses. Most research afterwards was more concerned with adverse effects of morphine as opposed to analgesic potential and opioids were not frequently used until the 1980s in veterinary practice, when an increased awareness of providing analgesia began to occur. Common routes for administration of opioids in veterinary medicine are intra-articular, intravenous, subcutaneous, intramuscular, intranasal, and transdermal. Common opioids in veterinary medicine are: morphine, fentanyl, and buprenorphine.
ADAPT 5 Berkeley Madonna COPASI: Biochemical System Simulator Ecolego Free simulation software: GNU MCSIM GNU Octave Matlab Archived 2021-05-05 at the Wayback Machine PottersWheel ModelMaker PhysioLab R deSolve package SAAM II Phoenix WinNonlin/NLME/IVIVC/Trial Simulator
Foreign versions of Lipitor and Celebrex were smuggled into the U.S. from South America and resold after being repackaged to conceal the true origin of the drugs. Counterfeit Lipitor was manufactured in South America and smuggled into the US, where it sold after commingling with the genuine foreign Lipitor. Participants conspired to buy, sell and traffic almost eight million dollars' worth of stolen Glaxo Smith Kline and Roche drugs, using fake pedigrees to launder the drugs and thereby concealing that they were stolen. There also were charges related to the sale of counterfeit Procrit, as well as counterfeit and misbranded Serostim and Neupogen. Procrit is an injectable drug used in the treatment of anemia, Serostim is Serono's brand name form of synthetic somatropin (i.e. human growth hormone formed using laboratory methods of genetic recombination) marketed for HIV-associated wasting, and Neupogen is an injectable drug used by cancer patients to stimulate the production of white blood cells in order to decrease the incidence of infections. In 2005, the FDA held a Congressional hearing to review the situation. The U.S. is an especially attractive market for counterfeiters, because 40% of worldwide annual prescription drug sales were made in the United States in 2007. In 2011, a "PROTECT IP Act" was proposed to deter advertising. Between 2002 and 2010, drug imports to the U.S. more than doubled, with 80% of drugs' active ingredients imported, now accounting for 40% of finished medicines. In 2015, the U.S.
== Synthesis == Generally, synthesis of the characteristic scaffold of ebselen, the benzoisoselenazolone ring system, can be achieved either through reaction of primary amines (RNH2) with 2-(chloroseleno)benzoyl chloride (Route I), by ortho-lithiation of benzanilides followed by oxidative cyclization (Route II) mediated by cupric bromide (CuBr2), or through the efficient Cu-catalyzed selenation / heterocyclization of o-halobenzamides, a methodology developed by Kumar et al. (Route III).
==== 5α-Reductase and androgenicity ==== Testosterone can be robustly converted by 5α-reductase into DHT in so-called androgenic tissues such as skin, scalp, prostate, and seminal vesicles, but not in muscle or bone, where 5α-reductase either is not expressed or is only minimally expressed. As DHT is 3- to 10-fold more potent as an agonist of the AR than is testosterone, the AR agonist activity of testosterone is thus markedly and selectively potentiated in such tissues. In contrast to testosterone, DHT and other 4,5α-dihydrogenated AAS are already 5α-reduced, and for this reason, cannot be potentiated in androgenic tissues. 19-Nortestosterone derivatives like nandrolone can be metabolized by 5α-reductase similarly to testosterone, but 5α-reduced metabolites of 19-nortestosterone derivatives (e.g., 5α-dihydronandrolone) tend to have reduced activity as AR agonists, resulting in reduced androgenic activity in tissues that express 5α-reductase. In addition, some 19-nortestosterone derivatives, including trestolone (7α-methyl-19-nortestosterone (MENT)), 11β-methyl-19-nortestosterone (11β-MNT), and dimethandrolone (7α,11β-dimethyl-19-nortestosterone), cannot be 5α-reduced. Conversely, certain 17α-alkylated AAS like methyltestosterone are 5α-reduced and potentiated in androgenic tissues similarly to testosterone. 17α-Alkylated DHT derivatives cannot be potentiated via 5α-reductase however, as they are already 4,5α-reduced.
Sources: en.wikipedia.org
Tanaka Team have developed a diagnostic technology that enables early detection of diseases from a small amount of blood. By artificially modifying antibodies with polyethylene glycol at their base, the arms can move like springs, allowing simultaneous binding to antigens. In experiments with protein fragments related to Alzheimer's disease, the modified antibodies captured antigens more than 100 times more strongly than conventional antibodies. Later improvements enabled glycan analysis from trace mixed samples without peptide selection, leading to the detection of Alzheimer’s-related proteins from 1 mL of blood and the identification of eight previously unknown related substances. This technology is expected to contribute to the early detection of various diseases, including Alzheimer’s disease and prostate cancer. The research originated from work awarded the Nobel Prize in 2002, though the initial methods lacked sufficient sensitivity for medical applications. In 2009, it was selected for the FIRST Program, Development of Next-Generation Mass Spectrometry Systems and Contributions to Drug Discovery and Diagnosis, which provided about 4 billion yen over five years. With a team of around 60 researchers, a breakthrough analytical method was developed within a year, achieving up to a 10,000-fold increase in sensitivity. In November 2011, the team described the results as a technology applicable to early diagnosis and antibody-based drug development, publishing findings in the electronic edition of an English journal issued by the Japan Academy.
The substance quickly penetrates the cornea and reaches the aqueous humour. It is reduced to dihydrolevobunolol, which is equally active, in the eye's tissues. The drug starts to lower intraocular pressure within an hour, reaches its maximum effect after two to six hours, and remains effective for up to 16 hours. It has an elimination half-life of six hours and is mainly excreted via the kidney.
Blumenthal was inspired as a teenager by trips to the Michelin-starred restaurants in France and the work of Harold McGee. McGee's work in particular led him to question traditional cooking techniques and approaches which resulted in combinations which may at first appear unusual. Blumenthal incorporates psychology and the perception of diners into his dishes. He gave the example of a dish of sardine on toast sorbet: "The brain will be trying to tell the palate to expect a dessert and you will therefore be tasting more sweetness than actually exists." The Fat Duck serves a tasting menu. Dishes served include palate cleansers made of vodka and green tea, frozen in liquid nitrogen, a snail porridge described by one food critic as "infamous", and ice creams of both crab, and egg and bacon, each of which drew media attention. The mock turtle soup has an Alice in Wonderland theme, whereby a fob watch formed of freeze-dried beef stock covered with gold leaf is dropped into a teacup by a waiter, who pours a beef stock "tea" poured over it that dissolves the gold and the watch. A plate of ox tongue and vegetables is served alongside to place into the soup. Toast sandwiches, developed for an appearance on Heston's Feasts, are served as a side dish. Dishes are served with additional sensory inputs, such as "Sounds of the Sea", a plate of seafood served with a seafood foam on top of a "beach" of tapioca, breadcrumbs and eel. Alongside the dish, diners are given an iPod to listen to crashing waves whilst they eat.
=== Chemical synthesis === Droplet-based microfluidics has become an important tool in chemical synthesis due to several attractive features. Microscale reactions allow for cost reduction through the usage of small reagent volumes, rapid reactions in the order of milliseconds, and efficient heat transfer that leads to environmental benefits when the amount of energy consumed per unit temperature rise can be extremely small. The degree of control over local conditions within the devices often makes it possible to select one product over another with high precision. With high product selectivity and small sizes of reagents and reaction environments come less stringent reaction clean-up and smaller footprint. Microdispersed droplets created by droplet-based chemistry are capable of acting as environments in which chemical reactions occur, as reagent carriers in the process of generating complex nanostructures. Droplets are also capable of being transformed into cell-like structures which can be used to mimic humans' biological components and processes. As a method of chemical synthesis, Droplets in microfluidics devices act as individual reaction chambers protected from contamination through device fouling by the continuous phase. Benefits of synthesis using this regime (compared to batch processes) include high throughput, continuous experiments, low waste, portability, and a high degree of synthetic control. Some examples of possible syntheses are the creation of semiconductor microspheres and nanoparticles.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.